A short course of menotropin after clomiphene failure in infertile women with luteal phase defects.
Twenty-four women with luteal phase defects who were ovulatory on clomiphene therapy with or without human chorionic gonadotropin (hCG) at midcycle for three to eight cycles yet failed to produce a live birth were treated with a short course of menotropin (hMG-S), one to two ampules for five days in the early follicular phase followed or not followed by hCG at midcycle for three to eight cycles. The luteal phase defect was diagnosed with repeat endometrial biopsies with a lag time of three or more days prior to clomiphene therapy. A complete infertility workup revealed only eight patients (33%) with a purely endocrine factor (luteal phase defect). The rest (16 patients, or 67%) had one or two additional infertility factors. Two abortions occurred in this group during clomiphene therapy, while five pregnancies (four live births and one spontaneous abortion) occurred during hMG-S therapy. The ovulation rates were similar for hMG-S (89%) and clomiphene (91%) therapy, but the frequency of a normal ovulatory cycle was significantly greater (P = .026) for hMG-S therapy (71%) than for clomiphene therapy (57%). The midluteal mean serum progesterone level was lower and the mean luteal length shorter in the cycles with less than 130 ng/mL/d of total integrated luteal progesterone. The postcoital test results showed better cervical mucus, with increased mucus volume and better fluidity and spinnbarkeit, in hMG-S cycles than in clomiphene cycles. It appears that hMG-S treatment can improve ovarian function and achieve successful pregnancy in patients with luteal phase defects who fail to produce a live birth during clomiphene treatment.
Wu
C H
CH
Department of Obstetrics and Gynecology, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania 19107.
D000328:Adult; D001835:Body Weight; D002582:Cervix Mucus / Q000187:drug effects; D002996:Clomiphene / Q000494:pharmacology / Q000592:standards / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D008183:Luteal Phase / Q000187:drug effects; D008596:Menotropins / Q000494:pharmacology / Q000592:standards / Q000627:therapeutic use*
D002996:Clomiphene; D008596:Menotropins